Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 25;12:830124. doi: 10.3389/fonc.2022.830124

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Li, Chen, Lin, Zhang, Lai, Li, Lin, Guo, Xiao, Mok, Ren, Wen, Cao, Lin, Qi, Liu and Liao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Kyoto Encyclopedia of Genes and Genomes analysis reveals distinct pathways in NSTs and STs tumors of TNBC. In total, 36.2% of the NSTs patients and 78.6% of the STs patients had at least one clinically relevant genomic alteration in genes involved in the PI3K-AKT signaling pathways, respectively. (A) Summary of the features of the PI3K-AKT signaling pathways genomic alteration of the 32 patients with TNBC. Tumor samples were grouped according to histologic types as: no-special type (IDC-NSTs, n=21) and special type (STs, n=11). (B) Comparison of the features of the PI3K-AKT signaling pathways genomic alteration between NSTs and STs TNBC patients. (C) Comparison of the features of the PI3K-AKT signaling pathways genomic alteration among STs TNBC patients. TNBC, triple-negative breast cancer; NST, no-special type; ST, special type; TMB, tumor mutation burden.